Continuous Glucose Monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over all outstanding patent disputes relating to their glucose monitoring products, which estimate ...

Abbott and Dexcom settled all patent lawsuits related to continuous glucose monitors (CGMs). The two competitors, who lead the U.S. market for CGMs, agreed on Dec. 20 to resolve all outstanding ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, ...

DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their continuous glucose monitors for people with diabetes—just weeks after a ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company ...